Download PDF
Exp Clin Endocrinol Diabetes 2007; 115(5): 308-316
DOI: 10.1055/s-2007-961797
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York

Insulin Resistance and Insulin Secretion in Non-diabetic Acromegalic Patients

M. Coculescu 1 , 2 , D. Niculescu 1 , 2 , R. Lichiardopol 3 , 4 , M. Purice 2
  • 1Carol Davila University, Endocrinology, Bucharest, Romania
  • 2C.I. Parhon Institute of Endocrinology, Bucharest, Romania
  • 3Carol Davila University, Diabetes, Bucharest, Romania
  • 4N. Paulescu Institute for Diabetes and Metabolic Diseases, Bucharest, Romania
Further Information

Publication History

received 10. 6. 2006 first decision 24. 9. 2006

accepted 28. 11. 2006

Publication Date:
21 May 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Insulin resistance (IR) can be induced by high amounts of growth hormone (GH).

Aim: To set up, in acromegaly without diabetes mellitus, a correlation between the disease activity in GH-secreting adenoma (AA) - assessed by minimum GH serum level during an oral glucose tolerance test (OGTT) - and severity of insulin resistance (IR), assessed by HOMA-IR index.

Methods: 75 out of 88 consecutive patients with acromegaly hospitalized in our department were included in this study. 13 patients proved to have diabetes mellitus and were excluded. Serum glucose, GH and insulin levels were measured by immunoradiometricassay basal and at 30, 60 and 120 minutes after a 75 g OGTT in 88 patients with active or cured acromegaly. IR was assessed using HOMA-IR index (Homa-IR=basal serum glucose (mg/dl) x basal serum insulin (mU/L)/22.5 × 18). A value over 2.5 was considered indicating IR.

Results: Out of 75 patients without diabetes mellitus, 36 subjects (48%) were presenting with IR (34 with active disease, 2 cured). We found a significant positive correlation (r=0.56, p<0.001) between AA and HOMA-IR. The GH minimal level corresponding to the intersection of the exponential regression curve with the HOMA-IR level of 2.5 was 8.8 ng/mL, a cut-off point indicating IR with 82% specificity and 78% sensitivity. The odds ratio for developing IR becomes significant at a minimum GH level during OGTT of 2 ng/mL (odds ratio 7.6, 95% confidence interval 2-29).

Conclusions: The severity of IR revealed by acromegaly correlates with GH production. A GH serum level higher than 2 ng/mL during OGTT indicates an increased risk for developing IR. This cut-off level of GH can be used as one of criteria of cured disease, regarding the lack of metabolic effects.

Key words

acromegaly - growth hormone - insulin resistance

References

  • 1 Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.  N Engl J Med. 2006;  355 ((8)) 763-778
    CrossrefPubMedGoogle Scholar
  • 2 Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.  J Clin Endocrinol Metab. 2004;  89 ((4)) 1613-1617
    CrossrefPubMedGoogle Scholar
  • 3 Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.  Clin Endocrinol (Oxf). 2003;  59 ((4)) 492-499
    CrossrefPubMedGoogle Scholar
  • 4 Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.  J Clin Endocrinol Metab. 2005;  90 ((10)) 5684-5691
    CrossrefPubMedGoogle Scholar
  • 5 Bates AS, Van't Hoff W, Jones J. Does treatment of acromegaly affect life expectancy?.  Metabolism. 1995;  44 ((suplement 1)) 1-5
    PubMedGoogle Scholar
  • 6 Biering H, Knappe G, Gerl H, Lochs H. [Prevalence of diabetes in acromegaly and Cushing syndrome].  Acta Med Austriaca. 2000;  27 ((1)) 27-31
    CrossrefPubMedGoogle Scholar
  • 7 Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements.  J Clin Endocrinol Metab. 2004;  89 ((6)) 2789-2796
    CrossrefPubMedGoogle Scholar
  • 8 Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.  Diabetes Care. 2000;  23 ((1)) 57-63
    CrossrefPubMedGoogle Scholar
  • 9 Cappiello V, Ronchi C, Morpurgo PS, Epaminonda P, Arosio M, Beck-Peccoz P, Spada A. Circulating ghrelin levels in basal conditions and during glucose tolerance test in acromegalic patients.  Eur J Endocrinol. 2002;  147 ((2)) 189-194
    CrossrefPubMedGoogle Scholar
  • 10 Christy NP. Choosing the best treatment for acromegaly.  JAMA. 1982;  247 ((9)) 1320
    CrossrefPubMedGoogle Scholar
  • 11 Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.  Endocr Rev. 2004;  25 ((1)) 102-152
    CrossrefPubMedGoogle Scholar
  • 12 Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.  J Clin Endocrinol Metab. 2006;  91 ((4)) 1397-1403
    CrossrefPubMedGoogle Scholar
  • 13 Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.  J Clin Endocrinol Metab. 2002;  87 ((8)) 3537-3542
    CrossrefPubMedGoogle Scholar
  • 14 Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas.  Diabetes Care. 1999;  22 ((5)) 818-822
    PubMedGoogle Scholar
  • 15 Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins.  Endocr Rev. 2002;  23 ((6)) 824-854
    CrossrefPubMedGoogle Scholar
  • 16 Flier JS, Usher P, Moses AC. Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and insulin in human skin fibroblasts.  Proc Natl Acad Sci USA. 1986;  83 ((3)) 664-668
    PubMedGoogle Scholar
  • 17 Foss MC, Saad MJ, Paccola GM, Paula FJ, Piccinato CE, Moreira AC. Peripheral glucose metabolism in acromegaly.  J Clin Endocrinol Metab. 1991;  72 ((5)) 1048-1053
    PubMedGoogle Scholar
  • 18 Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement.  J Clin Endocrinol Metab. 2000;  85 ((2)) 526-529
    CrossrefPubMedGoogle Scholar
  • 19 Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults.  N Engl J Med. 1987;  317 ((3)) 137-140
    PubMedGoogle Scholar
  • 20 Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action.  Am J Physiol. 1986;  250 ((3 Pt 1)) E269-E273
    PubMedGoogle Scholar
  • 21 Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW. Long-term treatment outcome in acromegaly.  Growth Horm IGF Res. 2003;  13 ((4)) 185-192
    PubMedGoogle Scholar
  • 22 Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly.  J Clin Endocrinol Metab. 2004;  89 ((2)) 667-674
    CrossrefPubMedGoogle Scholar
  • 23 Jasper H, Pennisi P, Vitale M, Mella A, Ropelato G, Chervin A. Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score.  J Endocrinol Invest. 1999;  22 ((1)) 29-34
    PubMedGoogle Scholar
  • 24 Kalloo-Hosein HE, Whitehead JP, Soos M, Tavare JM, Siddle K, O'Rahilly S. Differential signaling to glycogen synthesis by the intracellular domain of the insulin versus the insulin-like growth factor-1 receptor. Evidence from studies of TrkC-chimeras.  J Biol Chem. 1997;  272 ((39)) 24325-24332
    CrossrefPubMedGoogle Scholar
  • 25 Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.  Clin Endocrinol (Oxf). 2000;  52 ((5)) 549-555
    CrossrefPubMedGoogle Scholar
  • 26 Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly.  Braz J Med Biol Res. 2001;  34 ((11)) 1429-1433
    PubMedGoogle Scholar
  • 27 Luft R, Cerasi E, Hamberger CA. Studies on the pathogenesis of diabetes in acromegaly.  Acta Endocrinol (Copenh). 1967;  56 ((4)) 593-607
    PubMedGoogle Scholar
  • 28 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 ((7)) 412-419
    Google Scholar
  • 29 Melmed S. Acromegaly. In: DeGroot L, Jameson J, editors. Endocrinology. 5th ed. Philadelphia: Elsevier Saunders 2006 p 411-428
    Google Scholar
  • 30 Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).  Eur J Endocrinol. 2004;  151 ((4)) 439-446
    CrossrefPubMedGoogle Scholar
  • 31 Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T. Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency.  J Clin Endocrinol Metab. 1998;  83 ((10)) 3476-3479
    CrossrefPubMedGoogle Scholar
  • 32 Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE, Alberti KG, Weeke J. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy.  J Clin Endocrinol Metab. 1992;  74 ((5)) 1012-1019
    CrossrefPubMedGoogle Scholar
  • 33 Poggi C, Marchand-Brustel Y, Zapf J, Froesch ER, Freychet P. Effects and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: comparison with insulin.  Endocrinology. 1979;  105 ((3)) 723-730
    PubMedGoogle Scholar
  • 34 Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.  J Clin Endocrinol Metab. 2005;  90 ((4)) 1972-1978
    CrossrefPubMedGoogle Scholar
  • 35 Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.  J Clin Endocrinol Metab. 2004;  89 ((2)) 658-661
    CrossrefPubMedGoogle Scholar
  • 36 Trainer PJ. Editorial: acromegaly-consensus, what consensus?.  J Clin Endocrinol Metab. 2002;  87 ((8)) 3534-3536
    CrossrefPubMedGoogle Scholar
  • 37 World Health Organisation . 1999;  , Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications Report of a World Health Organisation Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. Available from.
  • 38 Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers.  Diabetes Care. 2000;  23 ((2)) 171-175
    CrossrefPubMedGoogle Scholar

Correspondence

M. Coculescu

Carol Davila University

Endocrinology

37, Dionisie Lupu

Bucharest 020021

Romania

Phone: +40/21/319 8718

Fax: +40/21/319 8718

Email: M.Coculescu@uni-davila.ro

      >